» Articles » PMID: 31357959

Have We Achieved Adequate Recommendations for Target Volume Definitions in Anal Cancer? A PET Imaging Based Patterns of Failure Analysis in the Context of Established Contouring Guidelines

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2019 Jul 31
PMID 31357959
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There are different contouring guidelines for the clinical target volume (CTV) in anal cancer (AC) which vary concerning recommendations for radiation margins in different anatomical regions, especially on inguinal site. PET imaging has become more important in primary staging of AC as a very sensitive method to detect lymph node (LN) metastases. Using PET imaging, we evaluated patterns of LN spread, and examined the differences of the respective contouring guidelines on the basis of our results.

Methods: We carried out a retrospective study of thirty-seven AC patients treated with chemoradiation (CRT) who underwent FDG-PET imaging for primary staging in our department between 2011 and 2018. Patients showing PET positive LN were included in this analysis. Using a color code, LN metastases of all patients were delineated on a template with "standard anatomy" and were divided indicating whether their location was in- or out-field of the standard CTV as recommended by the Radiation Therapy Oncology Group (RTOG), the Australasian Gastrointestinal Trials Group (AGITG) or the British National Guidance (BNG). Furthermore, a detailed analysis of the location of LN of the inguinal region was performed.

Results: Twenty-two out of thirty-seven AC patients with pre-treatment PET imaging had PET positive LN metastases, accumulating to a total of 154 LN. The most commonly affected anatomical region was inguinal (49 LN, 32%). All para-rectal, external/internal iliac, and pre-sacral LN were covered by the recommended CTVs of the three different guidelines. Of forty-nine involved inguinal LN, fourteen (29%), seven (14%) and five (10%) were situated outside of the recommended CTVs by RTOG, AGITG and BNG. Inguinal LN could be located up to 5.7 cm inferiorly to the femoral saphenous junction and 2.8 cm medial or laterally to the big femoral vessels.

Conclusion: Pelvis-related, various recommendations are largely consistent, and all LN are covered by the recommended CTVs. LN "misses" appear generally cranially (common iliac or para-aortic) or caudally (inguinal) to the recommended CTVs. The established guidelines differ significantly, particular regarding the inguinal region. Based on our results, we presented our suggestions for CTV definition of the inguinal region. LN involvement of a larger number of patients should be investigated to enable final recommendations.

Citing Articles

Nodal Elective Volume Selection and Definition during Radiation Therapy for Early Stage (T1-T2 N0 M0) Perianal Squamous Cell Carcinoma: A Narrative Clinical Review and Critical Appraisal.

Spinelli L, Martini S, Solla S, Vigna Taglianti R, Olivero F, Gianello L Cancers (Basel). 2023; 15(24).

PMID: 38136378 PMC: 10741760. DOI: 10.3390/cancers15245833.


The Role of MRI and PET/CT in Radiotherapy Target Volume Determination in Gastrointestinal Cancers-Review of the Literature.

Secerov Ermenc A, Segedin B Cancers (Basel). 2023; 15(11).

PMID: 37296929 PMC: 10252061. DOI: 10.3390/cancers15112967.


[What does the general and abdominal surgeon need to know about oncologically oriented radiotherapy?].

Muller J, Trommer S, Meyer F, Lampe K, Croner R, Vordermark D Chirurgie (Heidelb). 2023; 94(5):441-452.

PMID: 36892602 PMC: 10156816. DOI: 10.1007/s00104-023-01820-1.


The Role of Positron Emission Tomography and Computed Tomographic (PET/CT) Imaging for Radiation Therapy Planning: A Literature Review.

Mallum A, Mkhize T, Akudugu J, Ngwa W, Vorster M Diagnostics (Basel). 2023; 13(1).

PMID: 36611345 PMC: 9818506. DOI: 10.3390/diagnostics13010053.


Influence of radiation treatment technique (IMRT vs. 3D-RT) on acute toxicity and prognostic factors for survival for anal cancer.

Sauter C, Peeken J, Borm K, Diehl C, Munch S, Combs S Sci Rep. 2022; 12(1):19914.

PMID: 36402828 PMC: 9675840. DOI: 10.1038/s41598-022-24362-8.


References
1.
Gerard J, Chapet O, Samiei F, Morignat E, Isaac S, Paulin C . Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature. Cancer. 2001; 92(1):77-84. DOI: 10.1002/1097-0142(20010701)92:1<77::aid-cncr1294>3.0.co;2-p. View

2.
Das P, Bhatia S, Eng C, Ajani J, Skibber J, Rodriguez-Bigas M . Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007; 68(3):794-800. DOI: 10.1016/j.ijrobp.2006.12.052. View

3.
Ajani J, Winter K, Gunderson L, Pedersen J, Benson 3rd A, Thomas Jr C . Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008; 299(16):1914-21. DOI: 10.1001/jama.299.16.1914. View

4.
Myerson R, Garofalo M, El Naqa I, Abrams R, Apte A, Bosch W . Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009; 74(3):824-30. PMC: 2709288. DOI: 10.1016/j.ijrobp.2008.08.070. View

5.
Hodges J, Das P, Eng C, Reish A, Beddar A, Delclos M . Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. Int J Radiat Oncol Biol Phys. 2009; 75(3):791-4. PMC: 6455914. DOI: 10.1016/j.ijrobp.2008.11.021. View